The age at which girls begin taking birth control is gradually decreasing, making them the main target of campaign ads. It is so frustrating to me to learn that these large drug companies are putting products on the market without properly disclosing their adverse side effects. Think of your daughter, sister, niece, friends- they need to hear about the harmful side effects of oral contraceptives.

Please view the New York Times article and check out the comments section. There are many powerful accounts of women that have been affected by Yaz.

We at Drug Alert Updates would love to help you if you or someone you know have been affected by using Yaz. Please contact us with any questions you may have.

Trasylol is commonly used to control bleeding in heart surgeries. It was approved by the FDA in 1993, and is a colorless solution administered through an IV during heart surgeries. When it first appeared on the market, it included a warning about possible anaphylactic reactions, but declined to note the possible links to renal toxicity.

The lawsuit, filed October 20 by James Foster Mathis, alleges he experienced renal failure after he was administered Trasylol on June 28, 2004, before an aortic valve replacement and coronary artery bypass graft.

“Trasylol was indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass surgery,” the suit states. “The effects of Trasylol use in cardiopulmonary bypass surgery involve a reduction in inflammatory response, which translates into a decreased need for allogenic blood transfusions and reduced bleeding.”

Since Trasylol’s approval by the FDA in 1993, 4.3 million patients have been subjected to the potentially lethal drug, Mathis claims. In 2005 alone, Trasylol generated about $293 million in sales, the complaint says.

Mathis says he suffered acute renal failure and permanent injuries as a result of his exposure to Trasylol. Numerous other lawsuits have been filed against Bayer for Trasylol use.

To read the entire article, view the West Virginia Record.

For more information on what you can do if you have been affected by Trasylol, please contact Drug Alert Updates.

Atkinson, age 33, states that Yaz is a dangerous prescription drug sold without adequate warnings about the risk of serious side effects. Atkinson alleges that Yaz is improperly advertised and over-promoted for its benefits of assisting in the treatment of acne.

“Bayer promoted Yaz with the slogan `the difference a little chemistry can
make,`” added Atkinson. “What Bayer did not disclose was how negative that
difference can be. Yaz gave me life-threatening injuries that have forever
altered my life.”

Atkinson was prescribed Yaz by her dermatologist for the treatment of acne. She was unaware that it had not been approved by the FDA, even though Bayer advertised it for preventing or reducing acne.

“Several months later, I developed sharp pains in my left shoulder and had
difficulty breathing,” Atkinson continued. “I went to my doctor for an
examination. Testing revealed multiple blood clots in both lungs. I was
hospitalized immediately. Fortunately, the treatments eliminated the blood
clots, but only one month later I was diagnosed with gallstones. I then had to undergo gall bladder surgery in January 2009. I have suffered months of anxiety and nausea related to these medical procedures and drugs given to treat the adverse side effects I developed from taking Yaz.”

Atkinson claims that she would not have experienced these life-threatening health effects if she had not taken Yaz or had been warned of the possible side effects. Bayer failed to warn doctors and consumers that Yaz is actually more dangerous than previous oral contraceptives.

For the complete story, visit Reuter’s.

Drug Alert Updates would like to help you if you or a loved one have been affected by Yasmin or Yaz. Please contact us for more information.

A renowned researcher estimated that up to 22,000 patient’s lives could have been saved if the FDA had removed Trasylol back in 2006 when the studies began.

60 Minutes shares an insightful video about Joe Randone and his family’s journey to sue Bayer after Joe’s death. Joe was born with a heart murmur, but went on to lead a normal active life. In January 2006, Joe checked himself into the hospital for a routine heart valve replacement surgery. He was told that his surgery had only a 5 percent risk of complications, and he would be able to leave the hospital 5 days after surgery.

Trasylol was put into Joe’s IV and remained on a steady drip for 4 hours. After the surgery, his family was told that there had been complications, but the doctors failed to go into detail. Shortly thereafter, Joe suffered 2 heart attacks and kidney failure. Randone’s surgeon noted that he suffered from “Aprotinin-induced graft thrombosis”. Aprotinin is the generic name for Trasylol, and thrombosis means blood clotting.
Joe was able to return home after the surgery, only to have multiple other health problems. He became so swollen that he couldn’t even shut his eyes. Joe’s eyes were sewn shut to protect his corneas, his gallbladder had to be removed and his legs had to be amputated due to poor circulation. Over the course of 8 months, Joe underwent 19 surgeries.

To make matters worse, Joe could have been given two different drugs without the consequences. Both drugs were found to be effective in studies conducted, without the adverse side effects. Joe eventually died in August 2006.

I truly feel that Bayer and the FDA are more concerned about profits than about protecting and maintaining the health of their consumers. After reading Joe’s story, I almost felt physically sick thinking about the numerous surgeries that his body had to go through, and all for what? Joe and thousands of other people could be leading perfectly healthy lives now if they had not been given Trasylol during surgery. It completely astounds me to think that a drug can be put on the market before it is proven to be completely safe. Studies are conducted to prove the effectiveness of a drug and are tested on a small group of people. If the drug proves to be effective and safe within the small test group, it will then go on the market. My question is: who is protecting the consumer if it is not the FDA or the manufacturer of the drug? The answer remains to be seen.

I urge you to share this story with loved ones and friends, regardless if they have been directly affected by Trasylol or not. No one should have to suffer through life-threatening health complications after taking this drug. Please contact Drug Alert Updates for more information on Trasylol.